Lexaria Bioscience announces that Chris Bunka, CEO of the Company, is stepping aside for the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Christopher is an industry veteran with more than three decades of experience in the medical device and pharmaceutical industries, with domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. His career includes a tenure with DUSA Pharmaceuticals, Inc. where he was part of team that led a start-up from its operational infancy, through commercialization and profitability and to its eventual sale to Sun Pharmaceuticals Industries. Bunka has been appointed as Executive Strategic Advisor to the management team where he will continue to provide support and advice to Lexaria. He also remains as Chairman of the Board of Directors of Lexaria and looks forward to providing more focused strategic leadership in that role. Most recently, Mr. Christopher was the Chief Financial Officer at InVivo Therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience Advances Drug Delivery with PharmaCO Partnership
- Lexaria Bioscience enters material transfer agreement for DehydraTECH research
- Lexaria Advances Drug Tolerability in Latest Study
- Lexaria Bioscience says second GLP-1 human pilot study shows zero adverse events
- Lexaria’s Study Suggests Improved Drug Absorption With Food